Volume 7, Issue 3, May 2018, Page: 80-83
Evaluation of Hematological Changes in HIV Infected Pregnant Women After Receiving HAART at Debremarkos Hospital Debremarkos, Ethiopia
Kassahun Dires, Department of Pharmacology, College of Medicine, Debreberhan University, Debreberhan, Ethiopia
Received: Jun. 25, 2018;       Accepted: Jul. 9, 2018;       Published: Aug. 15, 2018
DOI: 10.11648/j.cmr.20180703.15      View  271      Downloads  31
Abstract
Hematological complications are documented as the second most common cause of morbidity and mortality in HIV/AIDS patients. Drugs for HIV/AIDS showed side effects on different hematological parameters. This study was aimed at assessing the changes in hematological profile of HIV infected pregnant women after initiation of highly active antiretroviral treatment. Retrospective cohort study was conducted to assess the hematological changes in HIV infected pregnant women after initiation of highly active antiretroviral (HAART) at ART clinic of Debremarkos hospital in Ethiopia from May to August 2017. Data available between May 2008 and August 2017 was collected from 380 patient cards of pregnant women. The data was entered into Excel spread sheet and was transported into STATA software for analysis. All data were presented as mean ± Standard error of the mean. Comparisons were made using the Paired T-test. A p-value of <0.05 was considered as a statistically significant difference. The result from the present study shows that the HAART initiation in pregnant women with HIV increases the CD4 cell count, the mean corpuscular hemoglobin concentration, white blood cell count, lymphocyte count and total mid cell count at ninety-five percent confidence interval. From the total of 380 patient cards with complete CD4 count, 200 patient cards were recorded with TDF/3TC/EFV ART regimen. The remaining 180 patient cards were documented with AZT/3TC/NVP regimen. Comparing the effect of the two Regimens on CD4 count, TDF/3TC/EFV increases the CD4 count significantly in pregnant women with HIV (p<0.0001). The other regimen (AZT/3TC/NVP) also increases the CD4 count from initial value but this increase in CD4 count after AZT/3TC/NVP initiation in pregnant women with HIV is not statistically significant (P>0.05). HAART initiation in pregnant women with HIV increases lymphocyte count, total mid cell count, red blood cell count, white blood cell count, total hemoglobin, hematocrit, mean cell volume and total platelet. On the contrary, the initial value of granulocyte count, mean cell hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width and mean platelet volume decreases after antiretroviral treatment in pregnant women with HIV.
Keywords
Hematological Parameters, HAART, HIV Positive Pregnant Women
To cite this article
Kassahun Dires, Evaluation of Hematological Changes in HIV Infected Pregnant Women After Receiving HAART at Debremarkos Hospital Debremarkos, Ethiopia, Clinical Medicine Research. Vol. 7, No. 3, 2018, pp. 80-83. doi: 10.11648/j.cmr.20180703.15
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
WHO, HIV report 2015
[2]
Ethiopia, HIV report 2015.
[3]
Omoregie R, Omokaro EU, Palmer O, Ogefer HO, Egbeobauwuaye A, Adeghe JE, et al. Prevalence of anemia among HIV-infected patients in Benin City, Nigeria. Tanzania J of Health Res. 2009; 11(1). 1-4.
[4]
Anastos K, Kalish LA, Hessol N, Weiser B, Melnick S, Burns D. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women’s interagency HIV study. AIDS. 1999; 13(17):17–26.
[5]
Sabin CA, Griffioen A, Yee TT, Emery VC, Herrero-Martinez E, Phillips AN. Markers of HIV-1 disease progression in individuals with hemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet. 2002; 360:1546–51.
[6]
Harbol AW, Liesveld JL, Simpson-Haidaris PJ, Abboud CN. Mechanisms of cytopenia in human immunodeficiency virus infection. Blood Rev. 1994; 8:241–51.
[7]
Akhtar M. Hematological Abnormalities among HIV/AIDS Patients on Zidovudine Containing Anti-retroviral Therapy. Ann. Pak. Inst. Med. Sc. 2008; 4(3): 132-135.
[8]
National Institute for Allergy and Infectious Disease (NIAID), Division of AIDS (2009). Table for grading the severity of adult and pediatric adverse events, version 1. 0 (2004), Clarification Augus 2009. Available at: http://rsc.tech-res
[9]
Vrisekoop N, Gent R, Boer AB, Otto SA, borleffs J, Steingrover R, et al. Restoration of the CD4 cell compartment after long term Highly Active Antiretroviral Therapy without Phenotypical Signs of Accelerated Immunological AgingJ. Immunol. 2008; 181:1573-1581.
[10]
Ziske J, Kunz A, Sewangi J et al. Hematological changes in women and infants exposed to an AZT-containing regimen for prevention of mother to child transmission of HIV in Tanzania. Plos One. 2013; 8(2):1-9.
[11]
Daniel N, Aryee T and Evelyn A. Profiling Hematological Changes in HIV Patients Attending Fevers Clinic at the Central Regional Hospital in Cape Coast, Ghana: A Case-Control Study. Arch. Appl. Sci. Res. 2011; 3 (5):326-331.
[12]
Osime EO, Aniegbune I. Some hematological and hem rheological changes in HIV- infected pregnant women on highly active antiretroviral therapy. Afr J Med Health Sci. 2015; 14(1):4-7.
[13]
Carbonara S, Fiorentino G, Serio G, Maggi P, Ingravallo G, Monno L, et al 2001. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect. May. 2001; 42(4):251-256.
Browse journals by subject